Fri, Jun 14, 8:38 PM (85 days ago)
Aura Biosciences, Inc. filed an amendment to its 2023 10-K report to update executive compensation details and correct the valuation of option awards per FASB ASC Topic 718. Key changes include the inclusion of J. Jill Hopkins, M.D. as a named executive officer and removal of Cadmus C. Rich, M.D. The amendment did not include financial statements or update other disclosures. Compensation for the named executives in 2023 included significant stock and option awards, with total compensation for CEO Elisabet de los Pinos at $3.54 million. The company also conducted two public offerings in 2022 and 2023, raising approximately $92.5 million and $99 million, respectively. Major shareholders include Matrix Capital Management and Eventide Asset Management.